Aerovate Therapeutics (NASDAQ:AVTE) Stock Price Down 3.9% Following Insider SellingTicker Report • 21 days ago
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report)'s share price fell 3.9% during trading on Wednesday following insider selling activity. The stock traded as low as $28.23 and last traded...
Share to Feed
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) insider Benjamin T. Dake sold 3,325 shares of the company's stock in a transaction dated Monday, April 1st. The stock was sold at an...
Related Stocks: AVTE...
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) shares reached a new 52-week high on Monday . The company traded as high as $30.73 and last traded at $28.72, with a volume of 14079 shares...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Last November, Aerovate Therapeutics (NASDAQ:AVTE) announced significant progress in the development of its lead candidate treatment for rare cardi...
Jefferies Financial Group started coverage on shares of Aerovate Therapeutics (NASDAQ:AVTE Free Report) in a research note issued to investors on Monday morning, Marketbeat.com reports. The...
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of...
AVTE's Full-Year Financials Reflect Ongoing Clinical Trial Investments and Intellectual Property ExpansionRelated Stocks: AVTE...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...